Generic Name and Formulations:
Metyrapone 250mg; caps.
Novartis Pharmaceuticals Corp
Indications for METOPIRONE:
Diagnostic drug for testing hypothalamic-pituitary ACTH function.
Single-dose short test: 30mg/kg (max 3g) at midnight with yogurt or milk. Blood sample for assay taken early the following morning. Give prophylactic dose of cortisone acetate 50mg. Multiple-dose test: Testing done over 6-day period. Administer 750mg every 4 hours for 6 doses on Day 5. See literature for results interpretation.
Single-dose short test: 30mg/kg (max 3g) at midnight with yogurt or milk. Blood sample for assay taken early the following morning. Give prophylactic dose of cortisone acetate 50mg. Multiple-dose test: Testing done over 6-day period. Administer 15mg/kg every 4 hours for 6 doses on Day 5. A minimum single dose of 250mg is recommended. See literature for results interpretation.
Adrenal cortical insufficiency.
May induce acute adrenal insufficiency in patients with reduced adrenal secretory capacity. Hypo- or hyperthyroidism. Pregnancy (Cat.C). Nursing mothers.
Adrenal corticosteroid synthesis inhibitor.
Discontinue drugs affecting pituitary and adrenocortical function prior to and during testing. May be antagonized by phenytoin; test may be inaccurate in patients taking phenytoin 2 weeks prior. Subnormal response with estrogen therapy. May potentiate acetaminophen toxicity.
Hypotension, GI upset, abdominal pain, headache, dizziness, sedation, rash; rare: decreased WBC, bone marrow depression.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds